Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
163.17
+5.69 (3.61%)
Jun 1, 2026, 1:53 PM EDT - Market open
Revolution Medicines Employees
Revolution Medicines had 883 employees as of December 31, 2025. The number of employees increased by 349 or 65.36% compared to the previous year.
Employees
883
Change (1Y)
349
Growth (1Y)
65.36%
Revenue / Employee
n/a
Profits / Employee
-$1,553,455
Market Cap
34.69B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 883 | 349 | 65.36% |
| Dec 31, 2024 | 534 | 156 | 41.27% |
| Dec 31, 2023 | 378 | 132 | 53.66% |
| Dec 31, 2022 | 246 | 58 | 30.85% |
| Dec 31, 2021 | 188 | 63 | 50.40% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Regeneron Pharmaceuticals | 15,410 |
| BeOne Medicines AG | 12,000 |
| BioNTech SE | 7,807 |
| Moderna | 4,700 |
| Genmab | 3,088 |
| Incyte | 2,844 |
| Alnylam Pharmaceuticals | 2,500 |
| argenx SE | 1,863 |
RVMD News
- 2 hours ago - Wedbush reiterates Outperform on Revolution Medicines after ASCO data - TheFly
- 2 hours ago - Revolution Medicines price target raised to $195 from $169 at H.C. Wainwright - TheFly
- 4 hours ago - Revolution Medicines price target raised to $195 from $165 at Oppenheimer - TheFly
- 7 hours ago - Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's - Reuters
- 18 hours ago - Revolution Medicines Transcript: Status update - Transcripts
- 18 hours ago - Revolution Medicines Slides: Status update - Filings
- 20 hours ago - Revolution Medicines announces results from Phase 3 RASolute 302 trial - TheFly
- 1 day ago - Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer - GlobeNewsWire